For UK Medical Media

First of its kind study to evaluate the effectiveness of combining established tolerable, generic medicines in the treatment of cancer

METRICS study investigates a new treatment route for patients for whom standard treatments are not viable or may benefit from adding this treatment

London, UK, 2nd September, 2014 – The Care Oncology Clinic, based in Harley Street, London announced today that it is recruiting patients onto a first-of-its-kind medical study to evaluate the effectiveness and tolerability of a unique combination of existing medicines in slowing the growth rate of tumours.

The open-label, observational METRICS study (Study of the Safety, Tolerability and Efficacy of Metabolic Treatments of Cancer), supported by The SEEK Group, aims to help patients who have been diagnosed with cancer and are unable to tolerate, see benefit from or have access to existing cancer therapies, or who may benefit from adding this treatment to the standard of care.

The METRICS study will examine the effect of tailored combinations of existing therapies, such as metformin, statins, doxycycline, mebendazole and ibuprofen, on the cancer cells’ metabolism. METRICS will also assess the potential of this regimen to reduce tumour growth, with a primary outcome measure of progression-free survival over five years, alongside secondary quality of life and tumour response outcomes. METRICS builds on existing, published studies\(^2-31\) that demonstrate the potential of these metabolic therapies to inhibit tumour growth as monotherapy.

Justin Stebbing, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust, is leading the study and comments, “The METRICS study provides another option for those people for whom standard cancer treatment regimens are not viable, tolerable, available or providing any benefit on a stand-alone basis. The medicines prescribed in the study are well-established, having been used by a large number of people over a long period of time, with known side effects. The medicines have also been shown to reduce cancer growth rates. By studying these treatments in combination, it is hoped we will see a slowing of or retarding of cancer growth rates above and beyond using the medicines on their own at the same time as providing the patient with an improved quality of life”.

Date of preparation: September 2014
The METRICS study builds on existing evidence, evaluating the effectiveness of proven treatments in combination, rather than individually, to determine whether combination treatment will provide improved results at the same time as offering a better quality of life for study participants. Over time, data generated by the study will be collected and analysed, using standard study procedures, and subsequently published. It is hoped, in time, that the results from this study will establish this regime as a new, affordable treatment option.

“The SEEK Group is delighted to be able to support the Care Oncology Clinic in making this important study a reality. We have a strong heritage and interest in research and development of medicines and new treatment advances, which allows us to bring safe, effective and low cost medicines to patients in the shortest possible time to help improve patient outcomes and quality of life. We are excited to think that the outcomes of the study have the possibility to help dramatically improve the future standard of cancer care” Robin Bannister, CEO Strategy and Business Development, The SEEK Group.

If you would like to find out more or understand whether your patients could benefit from participation in the study, please visit www.careoncologyclinic.com or call +44 (0)207 580 3266.

- ENDS -

For further information, please contact:
Robin Bannister, SEEK Pharmaceuticals, +44 7980 254 128, robin.bannister@seekacure.com
Glenn Mursell, Packer Forbes, 020 7036 8550, glenn@packerforbes.com
Harriet Reynolds, Packer Forbes, 020 7036 8550, harriet@packerforbes.com

Notes to Editors

Cancer rates in the UK

There are around 330,000 new cases of cancer (excluding non-melanoma skin cancer) diagnosed each year in the UK, with more than 1 in 3 people likely to develop some form of cancer during their lifetime.39

About the study

The study will evaluate the effectiveness and tolerability of combinations of established medicines, with differing metabolic impacts, for their potential to slow-down the growth and proliferation of cancer cells. The study is open to patients for whom no other treatments are available; patients who
can no longer be treated for reasons of cumulative toxicity; patients who are intolerant of current chemotherapy drugs; patients on round 3 or 4 of chemotherapy with low probability of success and patients who refuse traditional chemotherapy.

The Care Oncology Clinic use medicines which lower cholesterol, lower glucose, impact on glycolysis, mitochondria and apoptosis (cell death). A range of well-established options is available in each of these categories. Examples of the medicines used include:

- Metformin \(^\text{3-11}\)
- Statins \(^\text{12-16}\)
- Doxycycline \(^\text{17-21}\)
- Mebendazole \(^\text{22-28}\)
- Ibuprofen \(^\text{29-31}\)

The study, launched in August 2014, already has a small number of patients enrolled and has recently been accepted by a number of NHS hospitals. The Care Oncology Clinic will continue to recruit patients into the study through each site and through patients directly with the support of their healthcare professional, until the target study number of 2,000 to 5,000 patients is reached. In the UK it is estimated that there are 500,000 existing patients who fit the study criteria with a further 150,000 eligible patients’ being diagnosed each year.

When studies are conducted on existing medicines the sponsoring company, in this case The SEEK Group, does not benefit from commercial protection. Therefore, patients are asked to contribute towards the cost of their consultation and treatment while on the study.

**About the Care Oncology Clinic**

The Care Oncology Clinic, Harley Street is an independent, private healthcare provider for the treatment of cancer. Through its leading oncology consultants, the Care Oncology Clinic is currently undertaking a study of medical treatments, which aims to provide an acceptable quality of life, while showing significant, positive results in fighting the disease.

Care Oncology Clinic oncology consultants:

- Professor Justin Stebbing, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust,
- Professor Angus Dalgleish, Foundation Chair of oncology at St George’s, University of London

Date of preparation: September 2014
• Dr David Feuer, Senior Registrar & Research Fellow at The Royal Marsden NHS Trust and St Bartholomews

About SEEK Pharmaceuticals

Founded in 2004, the SEEK Group, headquartered in London, is involved in research and development of over the counter and prescription medicines and management and operation of clinics. It undertakes all these activities in order to bring safe, effective and low cost medicines to patients in the shortest possible time to radically improve human health in major disease areas.

The SEEK group together with other investors are providing financial backing to the Care Oncology Clinic to facilitate the running of the study. As the medicines involved are existing, generic therapies, The SEEK Group does not hold any commercial interest in the medicines and is acting on its ethos of bringing safe, effective and low costs medicines to patients in the shortest time possible to radically improve human health in cancer www.seekacure.com.
References

   Last accessed 27.08.14
8. Landman GWD, et al. Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes. Diabetes Care, Volume 33, Number 2, February 2010
24. Pantziarka P, et al. Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. ecancer 2014, 8:443
33. Dolfi SC, et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer & Metabolism 2013, 1:20